Gray 2016.

Methods	Randomized controlled phase II
Participants	56 participants with epithelial ovarian cancer
Interventions	Mucin 1 targeted dendritic cell vs standard of care
Outcomes	Progression‐free survival Overall survival Immune response
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised trial
Allocation concealment (selection bias)	Low risk	Randomised trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’